Drug treatment of schizophrenia in the 1990s. Achievements and future possibilities in optimising outcomes

Drugs

Volumn 53, Issue 6, 1997, Pages 915-929

  Fleischhacker, W Wolfgang ^a   Hummer, Martina ^a  

^a UNIVERSITY HOSPITAL INNSBRUCK   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; BENZODIAZEPINE DERIVATIVE; CHLORPROMAZINE; CLOZAPINE; FLUPHENAZINE; HALOPERIDOL; LITHIUM; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE; SERTINDOLE; ZOTEPINE;

ARTICLE; CLINICAL TRIAL; DRUG BLOOD LEVEL; DRUG CHOICE; DRUG TOLERABILITY; EXTRAPYRAMIDAL SYMPTOM; FUTUROLOGY; HUMAN; LONG TERM CARE; MAINTENANCE THERAPY; META ANALYSIS; ORAL DRUG ADMINISTRATION; SCHIZOPHRENIA; TARDIVE DYSKINESIA;

EID: 0031005967     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-199753060-00002     Document Type: Article

References (151)

1. Meise U, Kurz M, Fleischhacker WW. Antipsychotic maintenance treatment of schizophrenia patients: is there a consensus? Schizophr Bull 1994; 20: 215-25
2. Kissling W. Compliance, quality assurance and standards for relapse prevention in schizophrenia. Acta Psychiatr Scand 1994; 89 Suppl. 382: 16-24
3. Bäuml J, Kissling W, Buttner P, et al. Informationszentrierte Patienten- und Angehörigengruppen zur Compliance-verbesserung bei schizophrenen Psychosen. Verhaltens-therapie 1993; 3 Suppl. 1: 1-96
4. Goldstein MJ. Psychoeducational and family therapy in relapse prevention. Acta Psychiatr Scand 1994; 89 Suppl. 382: 54-7
5. Casey DE. Extrapyramidal syndromes: epidemiology, pathophysiology and the diagnostic dilemma. CNS Drugs 1996; 5 Suppl. 1: 1-12
6. Whitworth AB, Fleischhacker WW. Adverse effects of antipsychotic drugs. Int Clin Psychopharmacol 1995; 9 Suppl. 5: 21-7
7. Fleischhacker WW, Meise U, Günther V, et al. Compliance with antipsychotic drug treatment: influence of side effects. Acta Psychiatr Scand 1994; 89 Suppl. 382: 11-5
8. Kane JM, Borenstein M. Compliance in the long-term treatment of schizophrenia. Psychopharmacol Bull 1985; 21: 23-7
9. Kanter J. Clinical case management: definition, principles, components. Hosp Commun Psychiatry 1989; 40: 362-8
10. Wirshing WC, Marder SR, Van Putten T, et al. Acute treatment of schizophrenia. In: Bloom FE, Kupfer DJ, editors. Psychopharmacology - the fourth generation of progress. New York: Raven Press, 1995: 1259-66
11. Kane J, Honigfeld G, Singer J, et al. Clozapine for the treatment-resistant schizophrenic. Arch Gen Psychiatry 1988; 45: 789-96
12. Hagger C, Buckley P, Kenny JT, et al. Improvement in cognitive functions and psychiatric symptoms in treatment-refractory schizophrenic patients receiving clozapine. Biol Psychiatry 1993; 34: 702-12
13. Meltzer HY, Burnett S, Bastani B, et al. Effects of six months of clozapine treatment on the quality of life of chronic schizophrenic patients. Hosp Commun Psychiatry 1990; 41: 892-7
14. Kurz M, Hummer M, Oberbauer H, et al. Extrapyramidal side effects of clozapine and haloperidol. Psychopharmacology 1995; 118: 52-6
15. Baldessarini RJ, Cohen BM, Teicher MH. Significance of neuroleptic dose and plasma level in the pharmacological treatment of psychoses. Arch Gen Psychiatry 1988; 45: 79-91
16. Rifkin A, Doddi S, Karagi B. Dosage of haloperidol for schizophrenia. Arch Gen Psychiatry 1991; 48: 166-70
17. van Putten T, Marder SR, Mintz J, et al. Haloperidol plasma levels and clinical response: a therapeutic window relationship. Am J Psychiatry 1992; 149: 500-5
18. McEvoy JP, Hogarty GE, Steingard S. Optimal dose of neuroleptic in acute schizophrenia. Arch Gen Psychiatiy 1991; 48: 739-45
19. Marder SR, Meibach RC. Risperidone in the treatment of schizophrenia. Am J Psychiatry 1994; 151: 825-35
20. Levinson DF, Simpson GM, Singh H, et al. Fluphenazine dose, clinical response, and extrapyramidal symptoms during acute treatment. Arch Gen Psychiatry 1990; 47: 761-8
21. Volavka J, Cooper T, Czobor P, et al. Haloperidol blood levels and clinical effects. Arch Gen Psychiatry 1992; 49: 354-61
22. Fleischhacker WW, Hummer M, Kurz M, et al. Clozapine dose in the United States and Europe: implications for therapeutic and adverse effects. J Clin Psychiatry 1994; 55 (9 Suppl. B): 78-81
23. Vanderzwaag C, McGee M, McEvoy JP, et al. Response of patients with treatment-refractory schizophrenia to clozapine within three serum level ranges. Am J Psychiatry 1996; 153: 1579-84
24. Devinsky O, Pacia SV. Seizures during clozapine therapy. J Clin Psychiatry 1994; 55 (9 Suppl. B): 153-6
25. Levinson DF, Simpson GM, Lo ES, et al. Fluphenazine plasma levels, dosage, efficacy, and side effects. Am J Psychiatry 1995; 152: 765-71
26. Volavka J, Cooper TB, Czobor P, et al. The relationship between plasma haloperidol concentrations and clinical results. Arch Gen Psychiatry 1996; 53: 1168-9
27. Potkin SG, Bera R, Gulasekaram B, et al. Plasma clozapine concentrations predict clinical response in treatment-resistant schizophrenia. J Clin Psychiatry 1994; 55 (9 Suppl. B): 133-6
28. Miller DD, Fleming F, Holman TL, et al. Plasma clozapine concentrations as a predictor of clinical response: a follow-up study. J Clin Psychiatry 1994; 55 (9 Suppl. B): 117-21
29. Kurz M, Hummer M, Kurzthaler I, et al. Efficacy of medium-dose clozapine for treatment resistant schizophrenia. Am J Psychiatry 1995; 152: 1690-1
30. Haring C, Fleischhacker WW, Schett P, et al. Influence of patient-related variables on clozapine plasma levels. Am J Psychiatry 1990; 147: 1471-5
31. Hiemke C, Weigmann H, Härtter S, et al. Elevated serum levels of clozapine after addition of fluvoxamine. J Clin Psychopharmacol 1994; 14: 279-81
32. Meltzer HY. Duration of a clozapine trial in neuroleptic-resistant schizophrenia [letter]. Arch Gen Psychiatry 1989; 46: 672
33. Levinson DF, Singh H, Simpson GM. Timing of acute clinical response to fluphenazine. Br J Psychiatry 1992; 160: 365-71
34. Shalev A, Hermesh H, Rothberg J, et al. Poor neuroleptic response in acutely exacerbated schizophrenic patients. Acta Psychiatr Scand 1993; 87: 86-91
35. Kinon BJ, Kane JM, Johns C, et al. Treatment of neuroleptic resistant schizophrenic relapse. Psychopharmacol Bull 1993; 29: 309-14
36. Lieberman JA, Safferman AZ, Pollack S, et al. Clinical effects of clozapine in chronic schizophrenia: response to treatment and predictors of outcome. Am J Psychiatry 1994; 151: 1744-52
37. Kane J, Honigfeld G, Singer J, et al. Clozapine for the treatment-resistant schizophrenic. Arch Gen Psychiatry 1988; 45: 789-96
38. Heinrich K, Klieser E, Lehmann E, et al. Risperidone versus clozapine in the treatment of schizophrenic patients with acute symptoms: a double blind, randomized trial. Prog Neuropsychopharmacol Biol Psychiatry 1994; 18: 129-37
39. Kurz M, Hummer M, Kurzthaler I, et al. Efficacy of medium-dose clozapine for treatment-resistant schizophrenia. Am J Psychiatry 1995; 152: 1690-1
40. Zarate CA, Cole JO. An algorithm for the pharmacological treatment of schizophrenia. Psychiatr Ann 1994; 24: 333-9
41. Salzman C. The use of ECT in the treatment of schizophrenia. Am J Psychiatry 1980; 137: 1032-41
42. Remington G, Bezchlibnyk-Butler K. Management of acute antipsychotic-induced extrapyramidal syndromes. CNS Drugs 1996; 5 Suppl. 1: 21-35
43. Fleischhacker WW, Roth SD, Kane JM. The pharmacologic treatment of neuroleptic-induced akathisia. J Clin Psychopharmacol 1990; 10: 12-21
44. Fleischhacker WW, Barnas C, Günther V, et al. Mood-altering effects of biperiden in healthy volunteers. J Affect Dis 1987; 12: 153-7
45. Fayen M, Goldman MB, Moulthrop MA, et al. Differential memory function with dopaminergic versus anticholinergic treatment of drug induced extrapyramidal symptoms. Am J Psychiatry 1988; 145: 483-6
46. Smith JM. Abuse of antiparkinsonian drugs - a review of the literature. J Clin Psychiatry 1980; 41: 351-4
47. Tandon R, Mann NA, Eisner WH, et al. Effect of anticholinergic medication on positive and negative symptoms in medication-free schizophrenic patients. Psychiatry Res 1990; 31: 235-41
48. Goff DC, Baldessarini RJ. Drug interactions with antipsychotic agents. J Clin Psychopharmacol 1993; 1: 57-67
49. WHO. Prophylactic use of anticholinergics in patients on long-term neuroleptic treatment. Br J Psychiatry 1990; 156: 412-4
50. Crow TJ, McMillan JF, Johnson AL, et al. The Northwick Park study of first episodes of schizophrenia: II. A randomized controlled trial of prophylactic neuroleptic treatment. Br J Psychiatry 1986; 148: 120-7
51. Loebel A, Lieberman J, Alvir J, et al. Time to treatment response in successive episodes of early onset schizophrenia [abstract]. Schizophr Res 1995; 15: 158
52. Wyatt RJ. Neuroleptics and the natural course of schizophrenia. Schizophr Bull 1992; 17: 325-51
53. Davis JM. Maintenance medication. In: Barnes TRE, editor. Depot neuroleptics: a consensus. London: Mediscript, 1988: 47-52
54. Kane JM, Lieberman JA. Maintenance pharmacotherapy in schizophrenia. In: Meltzer HY, editor. Psychopharmacology - the third generation or progress. New York: Raven Press, 1987: 1103-9
55. Kissling W. Duration of neuroleptic maintenance treatment. In: Kissling W, editor. Guidelines for neuroleptic relapse prevention in schizophrenia. Berlin: Springer, 1991: 94-112
56. Steingard S, Allen M, Schooler NR. A study of the pharmacologic treatment of medication-compliant schizophrenics who relapse. J Clin Psychiatry 1994; 55: 470-2
57. Möller HJ, van Zerssen D. Course and outcome of schizophrenia. In: Hirsch SR, Weinberger DR, editors. Schizophrenia. Oxford: Blackwell Science Ltd, 1995: 106-27
58. Gaebel W, Pietzcker A. Indikation zur neuroleptischen Langzeitmedikation - Standardverfahren oder individual-prognostisch geleitete Intervention? Nervenarzt 1983; 54: 467-76
59. Johnson DAW. Who should be treated? In: Kissling W, editor. Guidelines for neuroleptic relapse prevention in schizophrenia. Berlin: Springer, 1991: 78-84
60. Davis JM, Matalon L, Watanabe MD, et al. Depot antipsychotic drugs: place in therapy. Drugs 1994; 47: 741-73
61. Kissling W, Kane JM, Barnes TRE, et al. Guidelines for neuroleptic relapse prevention in schizophrenia: towards a consensus view. In: Kissling W, editor. Guidelines for neuroleptic relapse prevention in schizophrenia. Berlin: Springer, 1991: 155-63
62. Schooler NR, Levine J, Severe JB, et al. Prevention of relapse in schizophrenia: an evaluation of fluphenazine decanoate. Arch Gen Psychiatry 1980; 37: 16-24
63. Rifkin A, Quitkin F, Rabiner CJ, et al. Fluphenazine decanoate, fluphenazine hydrochloride given orally and placebo in remitted schizophrenics. Arch Gen Psychiatry 1977; 34: 43-7
64. Kane JM. Dosage and route of administration of neuroleptic drugs during different phases of a schizophrenic illness. In: Kissling W, editor. Guidelines for neuroleptic relapse prevention in schizophrenia. Berlin: Springer, 1991: 85-93
65. Altamura CA, Colacurcio F, Mauri MC, et al. Haloperidol decanoate in chronic schizophrenia: a study of 12 months with plasma levels. Prog Neuropsychopharmacol Biol Psychiatry 1989; 14: 25-35
66. Müller P. Zur Rezidivprophylaxe schizophrener Psychosen. Stuttgart: Enke, 1982
67. Hogarty GE, Goldberg SC, Schooler NR, et al. Drug and sociotherapy in the aftercare of schizophrenic patients: two year relapse rates. Arch Gen Psychiatry 1974; 31: 603-8
68. Gilbert PL, Harris MJ, McAdams LA, et al. Neuroleptic withdrawal in schizophrenic patients. Arch Gen Psychiatry 1995; 52: 173-88
69. Pietzcker A, Gaebel W, Köpcke W, et al. Intermittent versus maintenance neuroleptic long-term treatment in schizophrenia - 2-year results of a German multicenter study. J Psychiatr Res 1993; 27: 321-39
70. Carpenter WT, Hanlon TE, Heinrichs DW, et al. Continuous versus targeted medication in schizophrenic outpatients: outcome results. Am J Psychiatry 1990; 147: 1138-48
71. Herz MI, Glazer WM, Mostert MA, et al. Intermittent vs maintenance medication in schizophrenia: two-year results. Arch Gen Psychiatry 1991; 48: 333-9
72. Jolley AG, Hirsch SR, McRink A, et al. Trial of brief intermittent neuroleptic prophylaxis for selected schizophrenic outpatients: clinical outcome at one year. BMJ 1989; 298: 985-90
73. Schooler NR, Keith SJ, Severe JB, et al. Relapse and rehospitalization during maintenance treatment of schizophrenia: the effects of dose reduction and family treatment. Arch Gen Psychiatry. In press
74. Johnson DAW. Further observations on the duration of depot neuroleptic maintenance therapy in schizophrenia. Br J Psychiatry 1979; 135: 524-30
75. Davis JM, Kane JM, Marder S, et al. Dose response of prophylactic antipsychotics. J Clin Psychiatry 1993; 54 Suppl. 3: 24-30
76. Kane JM, Jeste DV, Barnes TRE, et al. Tardive dyskinesia: a task force report of the American Psychiatric Association. Washington, DC: American Psychiatric Association, 1942
77. Kane JM, Woerner M, Lieberman J. Tardive dyskinesia: prevalence, incidence and risk factors. J Clin Psychopharmacol 1988; 8: 52-6S
78. Gardos G, Casey DE, Cole JO, et al. Ten-year outcome of tardive dyskinesia. Am J Psychiatry 1994; 151: 836-41
79. Kane JM. Tardive dyskinesia: epidemiological and clinical presentation. In: Bloom FE, Kupfer DJ, editors. Psychopharmacology: the fourth generation of progress. New York: Raven Press, 1995: 1485-95
80. Lieberman JA, Saltz BL, Johns CA, et al. The effect of clozapine on tardive dyskinesia. Br J Psychiatry 1991; 158: 503-10
81. Dave M. Clozapine-related tardive dyskinesia. Biol Psychiatry 1994; 35: 886-7
82. Gardos G, Cole JO. The treatment of tardive dyskinesias. In: Bloom FE, Kupfer DJ, editors. Psychopharmacology: the fourth generation of progress. New York: Raven Press, 1995: 1503-11
83. Carpenter WT. The treatment of negative symptoms: pharmacological and methodological issues. Br J Psychiatry 1996; 168 Suppl. 29: 17-22
84. Siris SG. Depression and schizophrenia. In: Hirsch SR, Weinberger DR, editors. Schizophrenia. Oxford: Blackwell Science, 1995: 128-45
85. Liddle PF, Barnes TRE, Curson DA, et al. Depression and the experience of psychological deficits in schizophrenia. Acta Psychiatr Scand 1993; 88: 243-7
86. Barnes TR, Curson DA, Liddle PF, et al. The nature and prevalence of depression in chronic schizophrenic inpatients. Br J Psychiatry 1989; 154: 486-91
87. Petit M, Raniwalla J, Tweed J, et al. A comparison of an atypical and typical antipsychotic, zotepine versus haloperidol, in patients with acute exacerbation of schizophrenia: a parallel-group double-blind trial. Psychopharmacol Bull 1996; 32: 81-7
88. Buchanan RW, Carpenter WT. Domains of psychopathology: an approach to the reduction of heterogeneity in schizophrenia. J Nerv Ment Dis 1994; 182: 193-204
89. Barnas C, Stuppäck CH, Miller C, et al. Zotepine in the treatment of schizophrenic patients with prevailingly negative symptoms: a double-blind trial vs. haloperidol. Int Clin Psychopharmacol 1992; 7: 23-7
90. Dieterle DM, Ackenheil M, Müller-Spahn F, et al. Zotepine, a neuroleptic drug with a bipolar therapeutic profile. Pharmacopsychiatry 1987; 20: 52-7
91. Duinkerke SJ, Botter PA, Jansen AA, et al. Ritanserin, a selective 5-HT2/1C antagonist, and negative symptoms in schizophrenia: a placebo-controlled double-blind trial. Br J Psychiatry 1993; 163: 451-5
92. Rifkin A, Siris S. Drug treatment of acute schizophrenia. In: Meltzer HY, editor. Psychopharmacology - the third generation of progress. New York: Raven Press, 1987: 1095-101
93. Goff DC, Kamal KM, Sarid-Segal O, et al. A placebo-controlled trial of fluoxetine added to neuroleptics in patients with schizophrenia. Psychopharmacology 1995; 117: 417-23
94. Goff DG, Brotman AW, Waites M, et al. Trial of fluoxetine added to neuroleptics for treatment resistant schizophrenic patients. Am J Psychiatry 1990; 147: 492-4
95. Roy A. Relationship between depression and suicidal behavior in schizophrenia. In: DeLisi LE, editor. Depression in schizophrenia. Washington, DC: American Psychiatric Press, 1990
96. Goldstein JM. Pre-clinical pharmacology of new atypical antipsychotics in late stage development. Exp Opin Invest Drugs 1995; 4: 291-8
97. Coward DM. General pharmacology of clozapine. Br J Psychiatry 1992: 160 Suppl. 17: 5-11
98. Kanba S, Yagi G, Oguchi E, et al. Neuropharmacology of zotepine, an antimanic drug: a potent blocker of D2 and 5-HT2 receptors of human brain. Jpn J Psychiatr Neurol 1991; 45: 133-4
99. Roth BL, Craigo SC, Choudhary MS, et al. Binding of typical and atypical antipsychotic agents to 5 hydroxytryptamine-6 and 5-hydroxytryptamine-7 receptors. J Pharmacol Exp Ther 1994; 268: 1403-10
100. Otani K, Kondo T, Kaneko S, et al. Steady-state serum kinetics of zotepine. Human Psychopharmacol 1992; 7: 331-6
101. Fleischhacker WW, Barnas C, Stuppäck CH, et al. Zotepine vs. haloperidol in paranoid schizophrenia: a double-blind trial. Psychopharmacol Bull 1989; 25: 97-100
102. Klieser E, Lehmann E, Tegeler J. Double-blind comparison of 3 × 75mg zotepine and 3 × 4mg haloperidol in acute schizophrenics. Fortschr Neurol Psychiatr 1991; 51: 14-7
103. Wetzel H, von Bardeleben U, Holsboer F, et al. Zotepine versus perazine in paranoid schizophrenia: a double-blind controlled trial of antipsychotic efficacy. Fortschr Neurol Psychiatr 1991; 51: 23-9
104. Dieterle DM, Müller-Spahn F, Ackenheil M. Efficacy and tolerance of zotepine in a double-blind comparison with perazine in schizophrenics. Fortschr Neurol Psychiatr 1991; 51: 18-22
105. Fleischhacker WW, Barnas C, Stuppaeck C, et al. Zotepine vs. haloperidol in paranoid schizophrenia: a double blind trial. Psychopharmacol Bull 1989; 25: 97-100
106. Müller Spahn F, Dieterle D, Ackenheil M. Clinical efficacy of zotepine in the treatment of schizophrenic negative symptoms. Fortschr Neurol Psychiatr 1991; 51: 30-5
107. Fleischhacker WW, Barnas C, Stuppäck C, et al. Zotepine in the treatment of negative symptoms in chronic schizophrenia. Pharmacopsychiatry 1987; 20: 58-60
108. Wolfersdorf M, König F, Straub R, et al. Delusional depression: treatment with zotepine or haloperidol and antidepressants [abstract]. Pharmacopsychiatry 1993; 26: 215
109. Data on file, Knoll Pharmaceuticals, Nottingham, UK
110. Barnas C, Stuppäck C, Unterweger B, et al. Treatment of negative symptoms in schizophrenia with zotepine [letter]. J Clin Psychopharmacol 1987; 7: 370
111. Leysen JE, Gommeren W, Eens A, et al. Biochemical profile of risperidone, a new antipsychotic. J Pharmacol Exp Ther 1988; 247: 661-70
112. Byerly MJ, DeVane CL. Pharmacokinetics of clozapine and risperidone: a review of recent literature. J Clin Psychopharmacol 1996; 16: 177-87
113. Peuskens J. Risperidone in the treatment of patients with chronic schizophrenia: a multi-national, multi-centre, double-blind, parallel-group study versus haloperidol. Br J Psychiatry 1995; 166: 712-26
114. Emsley RA, McCreadie R, Livingston M, et al. Risperidone in the treatment of first-episode patients with schizophreniform disorder. Poster presented at 8th ECNP Congress; 1995 30 Sep-4 Oct: Venice
115. Möller HJ. The negative component in schizophrenia. Acta Psychiatr Scand 1995; 91 Suppl. 388: 11-4
116. Lindström E, Eriksson B, Hellgren A, et al. Efficacy and safety of risperidone in the long-term treatment of patients with schizophrenia. Clin Ther 1995; 17: 402-12
117. Lee H, Ryan J, Mullett G, et al. Neuroleptic malignant syndrome associated with the use of risperidone, an atypical antipsychotic agent. Human Psychopharmacol 1994; 9: 303-5
118. Levin GM, Lazowick, AL, Powell HS. Neuroleptic malignant syndrome with risperidone. J Clin Psychopharmacol 1996; 16: 192-3
119. Mandoki MW. Risperidone treatment of children and adolescents: increased risk of extrapyramidal side effects? J Child Adolesc Psychopharmacol 1995; 5: 49-67
120. Simeon JG, Carrey NJ, Wiggins DM, et al. Risperidone effects in treatment-resistant adolescents: preliminary case reports. J Child Adolesc Psychopharmacol 1995; 5: 69-79
121. Sternlicht HC, Wells SR. Risperidone in childhood schizophrenia [letter]. J Am Acad Child Adolesc Psychiatry 1995; 34: 5
122. Fulton B, Goa KL. ICI-204,636. An initial appraisal of its pharmacological properties and clinical potential in the treatment of schizophrenia. CNS Drugs 1995; 4: 68-78
123. Gefvert O, Lindstrom LH, Langstrom B, et al. Time course for dopamine and serotonin receptor occupancy in the brain of schizophrenic patients following dosing with 150 mg Seroquel™ tid [abstract]. Eur Neuropsychopharmacol 1995; 5: 347
124. Fleischhacker WW, Link CGG, Horne B, et al. A multicentre, double-blind, randomized comparison of dose and dose regimes of Seroquel™ in the treatment of patients with schizophrenia. Poster presented at the 34th ACNP Meeting; 1995 11-15 Dec: Sun Juan
125. Saller FC, Salama AI. Seroquel: biochemical profile of a potential atypical antipsychotic. Psychopharmacology 1993; 112: 285-92
126. Goldstein JM, Arvanitis LA. ICI 204,636 (Seroquel™): a dibenzothiazepine atypical antipsychotic. Review of preclinical pharmacology and highlights of phase II clinical trials. CNS Drug Rev 1995; 1: 50-73
127. Hirsch S, Link CG, Goldstein JM, et al. ICI 20,636: a new atypical antipsychotic drug. Br J Psychiatry 1996; 168 Suppl. 29: 45-56
128. Fabre LF, Arvanitis L, Pultz J, et al. Seroquel™ (ICI 204,636). a novel, atypical antipsychotic: early indication of safety and efficacy in patients with chronic and subchronic schizophrenia. Clin Ther 1995; 17: 366-78
129. Borison RL, Arvanitis LA, Miller BG, et al. ICI 204,636, an atypical antipsychotic: efficacy and safety in a multicenter, placebo-controlled trial in patients with schizophrenia. J Clin Psychopharmacol 1996; 16: 158-69
130. Seroquel: a putative atypical antipsychotic drug with serotonin-and dopamine-receptor antagonist properties. J Clin Psychiatry 1995; 56: 438-45
131. Link C, Arvanitis L, Miller B, et al. A multicenter, double-blind, placebo-controlled, evaluation of Seroquel™ in hospitalised patients with acute exacerbation of subchronic and chronic schizophrenia. Poster presented at the VIIth Congress of the European College of Neuropsychopharmacology; 1994 16-21 Oct: Jerusalem
132. Bymaster FP, Calligaro DO, Falcone JF, et al. Radioreceptor binding profile of the atypical antipsychotic olanzapine. Neuropsychopharmacol 1996; 14: 87-96
133. Robertson GS, Fibiger C. Effects of olanzapine on regional C-Fos expression in rat forebrain. Neuropsychopharmacology 1996; 14: 105-10
134. Stockton ME, Rasmussen K. Electrophysiological effects of olanzapine, a novel atypical antipsychotic, on A9 and A10 dopamine neurons. Neuropsychopharmacology 1996; 14: 97-104
135. Data on file, Eli Lilly and Company
136. Beasley CM, Tollefson G, Tran P, et al. Olanzapine versus placebo and haloperidol. Neuropsychopharmacology 1996; 14: 111-23
137. Beasley C, Tran P, Satterlee W, et al. Olanzapine versus placebo, results of the United States double-blind olanzapine trial. Poster presented at the XXth CINP Congress; 1996 Jun 23-27: Melbourne
138. Tollefson GD, Beasley CM, Tran PV, et al. Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial. Am J Psychiatr 1997; 154: 457-65
139. Tollefson GD, Sanger TM, Beasley CM, et al. The course of primary and secondary negative symptoms in a controlled trial with olanzapine. Poster presented at the XXth CINP Congress; 1996 Jun 23-27: Melbourne
140. Dunn CJ, Fitton A, Sertindole. CNS Drugs 1996; 5: 224-30
141. Skarsfeldt T. Differential effects of repeated administration of novel antipsychotic drugs on the activity of midbrain dopamine neurons in the rat. Eur J Pharmacol 1995; 281: 289-94
142. Van Kammen DP, McEvoy JP, Targum SD, et al. A randomized, controlled, dose-ranging trial of sertindole in patients with schizophrenia. Psychopharmacology 1996; 124: 168-75
143. Tamminga C, Mack R, Zhorowski J, et al. Efficacy and safety of three doses of sertindole and haloperidol in schizophrenic patients. Poster presented at the XXth CINP Congress; 1996 Jun 23-27: Melbourne
144. Hale A, van der Burght M, Wehnert A, et al. A European dose-range study comparing the efficacy, tolerability and safety of four doses of sertindole and one dose of haloperidol in schizophrenic patients. Poster presented at the XXth CINP Congress; 1996 Jun 23-27: Melbourne
145. Firschman A, Williams SA, Drury C, et al. Sustained 5HT2 receptor occupancy of ziprasidone using the PET ligand setoperone in healthy volunteers. Poster presented at the XXth CINP Congress; 1996 June 23-27: Melbourne
146. Seeger TF, Seymour PA, Schmidt AW, et al. Ziprasidone (CP-88,054): a new antipsychotic with combined dopamine and serotonin receptor antagonist activity. J Pharmacol Exp Ther 1995; 275: 101-13
147. Harrigan E, Morrissey M, Ziprasidone Working Group. The efficacy and safety of 28-day treatment with ziprasidone in schizophrenia/schizoaffective disorder. Poster presented at the XXth CINP Congress; 1996 Jun 23-27: Melbourne
148. Fleischhacker WW. New drugs for the treatment of schizophrenic patients. Acta Psychiatr Scand 1995; 91 Suppl. 388: 24-30
149. Gerlach J, Peacock L. New antipsychotics: the present status. Int Clin Psychopharmacol 1995; 10 Suppl. 3: 39-48
150. Deutch AY, Duman RS. The effects of antipsychotic drugs on Fos protein expression in the prefrontal cortex: cellular localisation and pharmacological characterization. Neuroscience 1996; 70: 377-89
151. Harrison PJ, Burnet PWJ. Antisense as an explanatory, experimental and therapeutic tool for psychiatric disorders. Psychol Med 1994; 24: 275-9